

Título del Proyecto	PRISM- “Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate de discovery and development of new treatments for social and cognitive deficits in AD,SZ and MD-PRISM”
Nº de expediente asignado	Grant Agreement No. 115916
Abstract	Social withdrawal is a common early symptom of many neurological disorders, including schizophrenia, Alzheimer’s disease, and major depressive disorder. However, the underlying, biological causes of this symptom are still poorly understood and may differ from one disease to another. The PRISM project will carry out a range of tests, including blood tests, brain scans, and measures of behavior, on patients with these all too common diseases in a bid to determine which biological parameters correlate with specific clinical symptoms, like social withdrawal. The hope is that the project’s findings will shed new light on the causes of mental illness and their symptoms and facilitate the development of much-needed new treatments.
Entidad Financiadora	IMI2(Innovative Medicines Initiative 2 Joint Undertaking)
Convocatoria:	H2020-JTI-IMI2-2015-03
Importe de la ayuda	648.000 €
Fechas de ejecución del proyecto	01/04/2016-31/03/2019
	The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No.115916.



innovative
medicines
initiative



Enlaces:

www.prism-project.eu

www.imi.europa.eu/projects-results/project-factsheets/prism